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Probiotic lactobacilli 
as a promising strategy 
to ameliorate disorders associated 
with intestinal inflammation 
induced by a non‑steroidal 
anti‑inflammatory drug
María José Martínez Monteros1, Carolina Maldonado Galdeano1,2, María Florencia Balcells1, 
Ricardo Weill3, Juan Andrés De Paula4, Gabriela Perdigón1 & Silvia Inés Cazorla1,2*
Damage to the small intestine caused by non‑steroidal anti‑inflammatory drugs (NSAIDs) occurs 
more frequently than in the upper gastrointestinal tract, is more difficult to diagnose and no effective 
treatments exist. Hence, we investigated whether probiotics can control the onset of this severe 
condition in a murine model of intestinal inflammation induced by the NSAID, indomethacin. Probiotic 
supplementation to mice reduce the body weight loss, anemia, shortening of the small intestine, 
cell infiltration into the intestinal tissue and the loss of Paneth and Goblet cells associated with 
intestinal inflammation. Furthermore, a high antimicrobial activity in the intestinal fluids of mice fed 
with probiotics compared to animals on a conventional diet was elicited against several pathogens. 
Interestingly, probiotics dampened the oxidative stress and several local and systemic markers of 
an inflammatory process, as well as increased the secretion of IL‑10 by regulatory T cells. Even more 
importantly, probiotics induced important changes in the large intestine microbiota characterized 
by an increase in anaerobes and lactobacilli, and a significant decrease in total enterobacteria. We 
conclude that oral probiotic supplementation in NSAID‑induced inflammation increases intestinal 
antimicrobial activity and reinforces the intestinal epithelial barrier in order to avoid pathogens and 
commensal invasion and maintain intestinal homeostasis.
The gastrointestinal (GI) tract is an organ system whereby a balance between the epithelial cells, the immune sys-
tem and the resident microbiota play a crucial role for maintaining intestinal homeostasis. The physical barriers 
include a single layer of epithelial cells, their intercellular tight junctions, and the mucus that covers the epithelial 
surface. Mucins, the major components of the mucus layer, are secreted by Goblet cells that are interspersed 
among enterocytes throughout the  epithelium1. The epithelial layer not only serves as a passive physical barrier 
between the host and the intestinal microbiota. Intestinal epithelial cells (IECs) sense external or endogenous 
danger signals and mount a robust immune  response2. When the barrier function is impaired, the contact of the 
intestinal mucosa with the resident colonic bacteria leads to intestinal disorders.
Moreover, Paneth cells, located at the bottom of the intestinal crypts, are responsible for the secretion of a 
diverse arsenal of antimicrobial peptides (AMPs) such as lysozymes, secretory phospholipase A2, defensins, 
defensin-like peptides and cathelicidins, which have high antimicrobial activity. This array of AMPs limits the 
invasion and adherence of pathogenic and commensal bacteria by disrupting the integrity of the bacterial cell 
membrane or  wall3. In the last years, increasing evidence suggests that an impaired or defective production of 
AMPs is already implicated in Crohn’s  disease4–7. Once the inflammatory response has been initiated, IECs play 
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an active role in the resolution of inflammation by secreting anti-inflammatory mediators that generally inhibit 
neutrophil function.
Inflammatory bowel disease (IBD) is the collective name for a group of chronic inflammatory gastrointes-
tinal disorders, including ulcerative colitis, Crohn’s disease (which constitutes the vast majority of the cases), 
and other less frequent conditions that share features of both disorders (non-classifiable inflammatory bowel 
disease and indeterminate colitis).
Although the mechanisms underlying the etiology of IBD remain largely unknown, they involve a complex 
interaction of genetic and environmental factors, in a background of oxidative stress together with a dysregulation 
of the enteric immune system and alterations in the intestinal  microbiome8–10. Drugs that have been linked to 
cause or worsen IBD-like conditions include isotretinoin, antibiotics, oral contraceptives, mycophenolate mofetil, 
etanercept, ipilimumab, rituximab, sodium phosphate and non-steroidal anti- inflammatory drugs (NSAIDs)11. 
Is attractive to suggest that the anti-inflammatory actions of NSAIDs are due to inhibition of cyclooxygenase 
(COX) COX-2, whereas the unwanted side-effects, such as irritation of the stomach lining, are due to inhibition 
of COX-112. NSAIDs long-term administration often causes gastrointestinal lesions characterized by a breaking 
down in epithelial tight junctions, reduction on mucus production, abnormal passage of luminal antigens and 
intestinal bacteria, and increases in the local and systemic inflammatory  response13,14.
No certified clinical strategies for preventing NSAID-induced small intestinal injury is currently available. The 
use of anti-TNFα and other cytokine monoclonal antibodies have been introduced both for inducing remission 
and for maintenance therapy in refractory forms of the disease. However, the persistent and marked blockage of 
TNF-α bioactivity may have a detrimental effect on acute intestinal  inflammation15,16.
Probiotics have emerged as an important tool for this devastating disease as they can modulate immune 
disturbances and intestinal  dysbiosis17–20. Probiotic lactobacilli adhering to mammalian tissues can establish 
an upheld crosstalk with the host reinforcing the intestinal barrier and leading to the competitive exclusion of 
 pathogens21,22.
We have previously demonstrated that oral lactobacillus administration increases the Paneth cells and the 
intestinal antimicrobial activity in healthy  mice23. Here, we explore two probiotic lactic acid bacteria (Lactobacil-
lus casei CRL 431 and Lactobacillus paracasei CNCM I- 1518) as promising weapons to counteract the intestinal 
inflammation induced by NSAIDs. We will focus here on the effect of orally administered probiotics as enhanc-
ers of the antimicrobial activity along the gastrointestinal tract and modulators of the intestinal microbiota, 
considering resident and pathogenic bacteria encountered at these specific sites involved in the pathogenesis of 
intestinal inflammation.
Results
Probiotic bacteria ameliorate clinical signs of intestinal inflammation induced by indometha‑
cin in mice. Animals fed with L. casei CRL 431 (Lc 431), L. paracasei CNCM I-1518 (Lp 1518), or water, for 
7 and 5 days, respectively, received two indomethacin injections in the last two days of probiotic supplementa-
tion. Weight loss being one of the clinical features of intestinal inflammation, was registered before and after the 
indomethacin injection. Importantly, we observed a significant body weight loss after indomethacin treatment 
in animals receiving a conventional diet (Indo group: -2.27) compared to healthy controls (p < 0.05). By contrast, 
mice with indomethacin-induced inflammation supplemented with the probiotics were even able to increase 
their body weight compared to those values registered before the injection of indomethacin (1.30 ± 0.97 and 
2.14 ± 0.52, for Lc 431 + IBD and Lp 1518 + IBD, respectively) (Fig. 1A). During the time analyzed none of the 
animals had diarrhea.
The physical appearance of mice was also evaluated, observing piloerection and a swollen appearance in 
those animals receiving the indomethacin injection in the absence of probiotic supplementation (Indo group). 
By contrast, Lc 431 + Indo and Lp 1518 + Indo animals, only showed small patches of piloerected hair and nor-
mal appearance (p < 0.05) (Fig. 1B,C). It is important to mention that those littermate animals receiving the 
oral supplementation with Lc 431 and Lp 1518, without the indomethacin injection, showed significant differ-
ences in their body weight and appearance with respect to healthy control animals on a conventional diet at the 
time analyzed (Fig. 1A,B). Since, in the absence of indomethacin-induced intestinal inflammation, the immune 
response elicited in mice upon the probiotic supplementation (Lc 431 and Lp1518 groups) has been extensively 
described by us, this group was not included in the following studies.
We then analyzed the presence of anemia, a clinical sign that is frequently observed in patients suffering from 
chronic inflammatory disorders. No differences were observed in hematocrit values before the indomethacin 
injections in the different groups (45 ± 1.56, 43 ± 1.44, 44 ± 1 0.5 and 43 ± 1.3% for healthy controls; Indo; Lc 
431 + Indo and Lp 1518 + Indo; respectively) (data not shown). By contrast, we observed a significant decrease in 
hematocrit, hemoglobin values and red blood cell counts in Indo animals compared to healthy controls (p < 0.05) 
after induced-intestinal inflammation. Importantly, these parameters were only slightly modified in Lc 431 + Indo 
and Lp 1518 + Indo, being not statistically different from healthy controls (Fig. 1D).
Mice were euthanized on day 8 and samples of small and large intestine were taken. We observed a significant 
shortening of the small intestine in Indo animals leading to a substantial shrinkage of the organ in comparison 
to healthy littermate controls (p < 0.01 and p < 0.005, respectively). These modifications, as well as those observed 
in the large intestine, were ameliorated in animals with Indo receiving the oral probiotic supplementation (Lc 
431 + Indo and Lp 1518 + Indo) (Fig. 2B–D).
The small intestine was then submitted to careful macroscopic observation, showing the presence of ulcers 
and a multitude of small points of light which conferred a granular appearance to the mucosa in the Indo groups 
(Fig. 2D). By contrast, no damage was observed in Lc 431 + Indo and Lp 1518 + Indo nor in the healthy controls 
for the macroscopic analysis.
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We then performed the histological analysis of the small intestine to further examine the effects of probiotic 
consumption on an intestinal inflammatory process. A normal architecture of the small intestine was shown 
in healthy control mice (Fig. 3A), by contrast, we observed in the hematoxylin–eosin staining of tissue section 
that the administration of indomethacin caused overt damage to intestinal villi. Irregular villi with variable 
diameters along the depth of single crypts of dilated crypts, villi that did not run parallel, and a marked inflam-
matory cell infiltration were observed (Fig. 3B,E). By contrast, intestinal villi exhibited a relatively normal struc-
ture without significant alterations in the mucosal architecture of mice with intestinal inflammation receiving 
probiotic supplementation (Lc 431 + Indo and Lp 1518 + Indo) (Fig. 3C,D). Additionally, these mice exhibited 
Lieberkühn crypts with similar length to those observed in healthy control animals, while mice with intestinal 
Figure 1.  Clinical features of intestinal inflammation in animals. Balb/c mice supplemented with Lactobacillus 
casei CRL 431 (Lc 431), Lactobacillus paracasei CNCM I-1518 (Lp 1518), or water, for 7 and 5 days, received 
indomethacin injections on the last two days. Additional controls fed with Lc 431, Lp 1518 or water, received 2 
PBS injections. (A) Body weight differences after and before the indomethacin injection. (B) Appearance score 
was evaluated according to Shrum et al.51. The line at the top of the bars indicates the comparison between the 
two groups, *p < 0.05. (C) Photography of mice. Panels I- and II- show important patches of piloerected hair 
pointed by black arrows, in the Indo group. By contrast, the coat is smooth in Lc 431 + Indo and Lp 1518 + Indo 
groups (Panel III- and IV-, respectively). (D) Evaluation of red blood cells on the day mice were euthanized. 
Stars show the comparison to the healthy control group. *p < 0.05.
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inflammation on a conventional diet showed an important hyperplasia of the crypt compared to healthy control 
mice (p < 0.001) (Fig. 3G–J).
Oral probiotic supplementation in indomethacin‑induced intestinal inflammation reinforces 
the intestinal barrier by increasing antimicrobial activity and Paneth cells. Considering indo-
methacin administration used to impairs the functions of the gut barrier, the number of Paneth and Goblet 
cells was determined in all the experimental animals. We observed a significant increase in Paneth cells in Lc 
431 + Indo and Lp 1518 + Indo compared to the Indo group (p < 0.05) (Fig. 4A). Moreover, the number of mucin-
secreting Goblet cells was significantly reduced in Indo (4.43 ± 0.33, mean ± S.E.M) compared to healthy controls 
(p < 0.0001). Importantly, oral probiotic supplementation was able to greatly increase the number of Goblet cells 
(6.41 ± 0.31 and 5.32 ± 0.28, mean ± S.E.M; for Lc 431 + Indo and Lp 1518 + Indo groups, respectively) (Fig. 4B).
Figure 2.  Intestinal damage in mice treated with indomethacin and supplemented with probiotics. Balb/c mice 
supplemented with Lactobacillus casei CRL 431 (Lc 431), Lactobacillus paracasei CNCM I-1518 (Lp 1518), or 
water, for 7 and 5 days, received indomethacin on the last two days. On day 8 mice were euthanized and the 
following parameters were evaluated: (A) small intestine length; (B) the ratio between the weight of the small 
intestine and the body of each animal; and (C) the ratio between the weight of each large intestine and the 
body of the animal. The line at the top of the bars indicates the comparison between the two groups. *p < 0.05, 
**p < 0.01, ***p < 0.001. (D) Representative photography of the small intestine of: Panel I and V- Healthy control; 
Panel II and VI- Indo; Panel III and VII- Lc 431 + Indo; and Panel IV and VIII- Lp 1518 + Indo mice, revealing 
the presence of ulcers (black arrows) and a mucosa with granular appearance (red arrows) in mice on a 
conventional diet treated with indomethacin. I-IV images were taken under observation with a Leica ES2 Stereo 
Microscope with 10 × High Eyepoint. V-VIII are images of the intestine after cutting them longitudinally.
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No bacterial translocation from the commensal microbiota to spleen or liver was observed in any of the exper-
imental animals. Those organs appeared to be sterile after serial dilution plating of the organs on agar medium.
While considering the resident and pathogenic flora encountered in the intestinal lumen to be involved in the 
pathogenesis of inflammatory processes along the gastrointestinal tract, the antimicrobial activity of the intestinal 
fluids in the experimental animals was analyzed. The increase under probiotic supplementation in the number 
of crypts containing Paneth cells was in accordance with the antimicrobial activity observed in the intestinal 
fluids of the mice. An altered intestinal antimicrobial activity in the Indo animals was revealed by a change in 
the growth kinetic of the pathogen, when Staphylococcus aureus and Salmonella enterica serovar Typhimurium 
were incubated in the presence of the intestinal fluid of those animals (13.42 ± 3.47 × 1010 and 10.56 ± 1.49 × 109 
for S. aureus and S. Typhimurium, respectively, vs 6.55 ± 1.55 × 1010 and 5.85 ± 1.32 × 109 for healthy controls). 
Additionally, a great decrease in the CFU/ml of S. aureus and S. Typhimurium was observed after their incuba-
tion with the intestinal fluids of Lc 431 + Indo and Lp 1518 + Indo, compared to those registered in mice on a 
conventional diet receiving the indomethacin injection (p < 0.05). More interestingly, the CFU of both pathogens 
in Lc 431 + Indo and Lp 1518 + Indo were similar to those registered in healthy mice controls (Fig. 5A,B).
The antimicrobial activity of the intestinal fluids was also evaluated against multi-resistant bacteria to several 
antibiotics. It is worth highlighting that a significant decrease in the CFU of K. pneumonia and E. aerogenes by 
plate count agar was observed after their incubation with the intestinal fluids of probiotic-fed mice (Lc 431 + Indo 
Figure 3.  Hematoxylin and eosin staining of small intestine tissue section. Balb/c mice supplemented with L. 
casei CRL 431 (Lc 431), L. paracasei CNCM I-1518 (Lp 1518), or water, for 7 and 5 days, received indomethacin 
injections on the last two days. On day 8 mice were euthanized and samples of the small intestine were taken for 
histological analysis. Representative micrographs of: (A,G) Healthy control; (B,E,H) mice on a conventional diet 
treated with indomethacin; (C,I) Lc 431 + Indo; and (D,J) Lp 1518 + Indo. (D) Inflammatory cells infiltrated in 
indomethacin-treated mice on a conventional diet. (F) Inflammation was qualitatively evaluated according to 
the number and spread of inflammatory foci from 0 to 4: 0, no leukocytic infiltration; 1, low level of leukocytic 
infiltration; 2, moderate level of leukocytic infiltration; 3, high level of leukocytic infiltration; and 4, transmural 
 infiltration54. *p < 0.05 ***p < 0.001. (K) Length of Lieberkühn crypt in the small intestine of experimental mice. 
Results (mean ± S.E.M.) are representative of three independent experiments. The line at the top of the bars 
indicates comparison between the two groups. ***p < 0.01. Magnification: (A-D) 100X, (E, G-J) 400X. Lines in 
panels G, H, I and J mean: 33.16, 53.26, 43.03 and 48.15 µm, respectively.
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Figure 4.  Mouse intestinal secretory cells in indomethacin-induced intestinal inflammation. Tissue sections 
of Balb/c mice orally supplemented with Lactobacillus casei CRL 431 (Lc 431), Lactobacillus paracasei CNCM 
I-1518 (Lp 1518), or water, for 7 and 5 days and receiving 2 indomethacin injections were stained with 
hematoxylin and eosin and examined by light microscopy. A blind histological test of the small intestine was 
performed by analyzing 5 slices of each organ and the percentages of (A) crypts with positive Paneth cells and 
(B) Goblet cells per villus were determined. Results were expressed as the number of Goblet cells per intestinal 
villus. The column bar shows a semi-quantitative evaluation for each group. Each bar represents the group 
mean ± S.E.M. Results are representative of three independent experiments. The line at the top of the bars 
indicates comparison between the two groups. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Figure 5.  Antimicrobial activity of intestinal fluids of indomethacin-treated mice. S. aureus (A), S. 
Typhimirium (B), K. pneumoniae (C) and E. aerogenes (D),  (109 CFU/ml), were incubated at 37 °C for 2 h in 
the presence of the intestinal fluids of: healthy control animals, or mice with induced intestinal inflammation 
receiving a conventional diet or probiotic supplementation (Indo; Lc 431 + Indo and Lp 1518 + Indo groups, 
respectively). After co-incubation, viable bacteria were determined by plate count agar. A set of serial dilutions 
were made and samples of each appropriate dilution were spread on top of solidified agar petri plates. Results 
(mean ± S.E.M) are representative of three independent experiments. Results were expressed as the differences 
in CFU/ml after and before the incubation of bacteria with the intestinal fluids. The line at the top of the bars 
indicates comparison between the two groups. *p < 0.05, **p < 0.01.
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and Lp 1518 + Indo) compared to the animals on a conventional diet receiving the indomethacin injection 
(p < 0.05, and p < 0.01) (Fig. 5C,D).
These results together indicate that the increase in probiotic-induced intestinal antimicrobial activity can 
contribute to restore the disruption of gut barrier integrity observed in the indomethacin-induced intestinal 
inflammation, preventing bacterial permanence in the intestinal tract leading to sustained inflammation and 
tissue damage.
Oral probiotic supplementation promotes a reduction in the intestinal inflammatory pro‑
cess in indomethacin‑induced intestinal inflammation. One of the mechanisms involved in the 
pathogenesis and establishment of IBD is a hyper activation of the proinflammatory pathways associated with 
a defective counter-regulatory mucosal immune response. Accordingly, in the intestinal fluids of Indo mice 
fed with a conventional diet we observed a significant increase in TNF-α levels as well us low levels of IL-10, 
compared to healthy mice controls (*p < 0.05) (Fig. 6). Interestingly, animals treated with indomethacin receiv-
ing oral probiotic supplementation exhibited lower levels of TNF-α in their intestinal fluids (Lc 431 + Indo: 
715 ± 71.09 pg/ml and Lp 1518 + Indo: 793.8 ± 97.07 pg/ml) compared to those littermates on a conventional diet 
(Indo: 1,202 ± 117.3 pg/ml) (Fig. 6A).
Notably, this dampening in proinflammatory cytokine secretion by intestinal epithelial cells was coupled with 
an enhancement of IL-10 in Lc 431 + Indo and Lp 1518 + Indo, (**p < 0.01 and *p < 0.05, respectively) in compari-
son to animals with intestinal inflammation fed on a conventional diet (Fig. 6B,D). These results highlight the 
role of probiotics to hold on the balance between TNF-α and IL-10; this fact being critical to preserve intestinal 
homeostasis in indomethacin-induced intestinal inflammation.
As additional markers of an inflammatory process, we measured the serum protein levels that are released into 
the blood when cells are damaged: lactate dehydrogenase (LDH) and C-reactive protein (CRP), an acute phase 
reactant. As shown in Fig. 6E indomethacin-treated mice receiving oral probiotic supplementation showed sig-
nificant lower serum LDH levels compared to those on a conventional diet (**p < 0.01 and *p < 0.05, Lc 431 + Indo 
and Lp 1518 + Indo, respectively). Similarly, mice with an intestine inflammatory process receiving a conventional 
diet exhibited higher CRP levels compared to those fed with probiotics (Indo: 5.96 ± 1.96 mg /ml, Lc 431 + Indo: 
3.39 ± 0.61 mg/ml and Lp 1518 + Indo:2.37 ± 0.28 mg/ml) (Fig. 6F).
Probiotic administration in indomethacin‑induced intestinal inflammation decreased the 
overproduction of reactive oxygen species (ROS) and proinflammatory cytokines by mac‑
rophages. An overwhelming reactive oxygen and nitrogen species generation has been implicated as media-
tors of mucosal injury in several inflammatory process. Accordingly, the endogenous generation of ROS by 
peritoneal macrophages from experimental mice was evaluated using the ROS-dependent conversion of the 
oxidative-sensitive probe H2DCFDA into the fluorescent dye dichlorofluorescein by flow cytometry. By a previ-
ous selection of the peritoneal macrophages in a forward versus side-scatter dot plot, a significant increase in the 
production of ROS in Indo mice was observed compared to healthy mice controls (*p < 0.05). More interestingly, 
oral probiotic supplementation in the mouse model of intestinal inflammatory process was able to significantly 
decrease the ROS production compared to those littermates on a conventional diet (IBD) (**p < 0.01) (Fig. 7A,B).
To further explore the modulation elicited by probiotics in reactive oxygen and nitrogen species, the levels 
of nitric oxide (NO) were measured at 16 h in the macrophage culture supernatant. In accordance with ROS 
production, a great reduction in NO levels was observed in Lc 431 + Indo and Lp 1518 + Indo with respect to 
IBD animals (Fig. 7C).
Finally, the production of macrophage proinflammatory cytokines playing an important role in the devel-
opment of inflammatory bowel disease was evaluated, finding an important decrease in the release of TNF-α, 
IL-6, IFN-γ and IL-12 indomethacin-treated mice fed with probiotics compared to those on a conventional diet 
(Fig. 7D–G). These results together showed that oral probiotic supplementation ameliorates indomethacin-
induced inflammatory responses elicited by macrophages mainly through a reduction in ROS and proinflam-
matory cytokine production and contributes to promoting intestinal homeostasis (Fig. 7H).
Probiotic supplementation in indomethacin‑treated mice promotes intestinal homeosta‑
sis. Finally, we analyzed the role of the large intestinal microbiota in the onset of intestinal inflammation. 
Colons of experimental mice were removed, homogenized and placed in agar plate medium specific for different 
bacteria. As shown in Fig. 8 a significant increase in total enterobacteria in the Indo group was observed com-
pared to healthy mice controls (*p < 0.05). Interestingly, in mice receiving oral probiotic supplementation (Lc 
431 + Indo and Lp 1518 + Indo) a slight decrease in total enterobacterial population was observed compared to 
those mice with intestinal inflammation on a conventional diet. As expected, animals fed with probiotic lactic 
acid bacteria exhibited higher levels in lactobacillus count. Moreover, a significant increase in total anaerobic 
bacteria was also observed in animals receiving probiotic lactic acid bacteria supplementation compared to 
healthy controls (Fig. 8A). These results suggest that in an intestinal inflammatory process the administration 
of Lc 431 and Lp 1518 promotes the expansion of protective microorganisms and the reduction of detrimental 
bacteria to maintain intestinal microbiota homeostasis.
As shown in Fig. 8B, a radar chart with three axes (enterobacteria, lactobacilli and anaerobes) showed the 
aforementioned modifications of the total colon microbiota in mice with an intestinal inflammatory process fed 
on a different diet.
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Discussion
The clinical management of patients with intestinal inflammation through completely safe and effective thera-
pies is still an unmet  need24. Although acid suppressants such as proton pump inhibitors (PPIs) and histamine 
 H2-receptor antagonists prevent NSAID-induced damages to the upper GI tract, these agents are not effective 
at preventing the small intestinal  injury25. There are evidences that PPIs exacerbated NSAIDs-induced small 
intestinal  damages26,27. Even more importantly, as compared with upper GI tract events requiring hospitaliza-
tion, small intestine cases were associated with higher rates of mortality and relapse, and significantly longer 
periods of  hospitalization25.
Understanding the mucosal immune mechanisms in states of health and intestinal disease provides the basis 
for the development of effective therapeutics aimed at resolving inflammation and preserving intestinal homeo-
stasis. As several studies suggest that intestinal inflammation may be the consequence of a primary deficiency 
Figure 6.  Cytokine secretion in the intestinal microenvironment of indomethacin-treated mice fed probiotics. 
TNF-α (A,C) and IL-10 (B,D) were determined in the (A,B) intestinal fluids and (C,B) supernatant of the 
epithelial cell culture from healthy control mice and animals with an intestine inflammation process receiving a 
conventional diet (Indo) or oral supplementation with probiotics (Lc 431 + Indo and Lp 1518 + Indo). Samples 
were assayed in duplicate by Capture ELISA. The results are representative of 3 independent experiments (n = 6). 
The line at the top of the bars indicates comparison between the 2 groups. *p < 0.05 and ** p < 0.01.
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Figure 7.  Release of reactive oxygen species and cytokine mediators of intestinal inflammation by 
macrophages. Balb/c mice supplemented with L. casei CRL 431 (Lc 431), L. paracasei CNCM I-1518 (Lp 
1518), or water, for 7 and 5 days, received indomethacin injections on the last two days. On day 8, mice were 
euthanized and samples of peritoneal macrophages were taken. ROS production as fluorescence units of 
oxidized dichlorodihydrofluorescein was detected by flow cytometry and (A) representative histograms and 
(B) mean fluorescence intensity (MFI) in experimental animals were shown. Peritoneal macrophages were 
incubated at 37 °C 5%  CO2 for 16 h and the supernatant collected for the determination of: (C) NO by Griess 
reagent; (D,E,F,G) proinflammatory cytokines by Capture ELISA. Results are expressed as mean ± SEM and are 
representative of at least three independent experiments. The line at the top of the bars indicates comparison 
between the 2 groups. *p < 0.05 and ** p < 0.01. (H) Radar chart plot of inflammatory mediators released by 
macrophages from the different experimental groups. Results are expressed as the ratio between each group and 
the healthy control mice.
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of innate and adaptive  immunity28, probiotics that are able to reinforce the complex intestinal immune system 
emerge as promising tools. Although some authors have reported the preventive effect of probiotics in disorders 
of the gastrointestinal tract by reducing damage in the small intestine, neutrophil infiltration, TNF-α and INF-γ 
 levels29–31, the mechanism by which they behave would not be fully elucidated.
Here we focus on the ability of L. casei CRL 431 and L. paracasei CNCM I- 1518 to preserve intestinal homeo-
stasis in an intestinal inflammatory process induced by indomethacin.
We observed that as intestinal inflammation was elicited by an indomethacin subcutaneous injection in 
experimental mice, the typical physical and clinical mice aspects were altered, which was reflected by significant 
weight loss, anemia, piloerection and swelling of the animals (Fig. 1). Additionally, as an indicator of the inflam-
matory process elicited in mice both the small and large intestine got shorter (Fig. 2). This inflammatory process 
seems to have caused excessive regenerative hyperplasia of the mucosa leading to a marked thickening of the 
intestinal wall and the onset of ulcers in the Indo animals receiving a conventional diet (Fig. 2).
Moreover, considering that histomorphology remains a powerful routine tool to evaluate intestinal inflamma-
tion, an exhaustive evaluation of the small intestine of the animals was conducted, revealing important alterations 
of the mucosal architecture. Irregular villi with different heights and widths, enlarged crypts of Lieberkühn and 
a marked inflammatory cell infiltration were observed in indomethacin-treated animals on a conventional diet 
(Fig. 3). This infiltration of inflammatory cells in the mucosa further damages the intestinal tissue, leading to a 
vicious circle. By contrast, the histological index determined for mice receiving the indomethacin injections upon 
the oral supplementation with L. casei CRL 431 or L. paracasei CNCM I- 1518 was similar to the healthy controls 
(Fig. 3). No significant damage in the shape of the intestinal tissue was observed in those animals with respect 
to controls. Our results suggest that probiotics administered during an intestinal inflammatory process reduce 
intestinal inflammation through a reinforcement of the intestinal epithelial barrier, particularly, through an 
increase in the cells responsible for mucus and AMPs production, Goblet and Paneth cells, respectively (Fig. 4).
The role of constitutive and inducible antimicrobial peptides in intestinal inflammation has been investigated 
thoroughly over the recent  years6,32–35. Accordingly, a reduced antimicrobial activity of the intestinal fluids of 
mice with intestinal inflammation was observed against pathogens that usually cause gastrointestinal infections 
or food poisoning (Fig. 5). By contrast, the CFU/ml of S. Typhimurium and S. aureus was significantly reduced 
after the incubation of these pathogens with the intestinal fluids from indomethacin-treated mice fed with 
probiotics compared to those on a conventional diet (Fig. 5), reaching counts similar to those observed in the 
presence of healthy control fluids.
Some antibiotics are effective in preventing damage to the small intestine induced by  NSAIDs36. However, 
NSAIDs are frequently prescribed to control chronic pain for a prolonged period, and long-term use of antibiot-
ics increases the risk of eliminating resident microbiota, inducing antibiotic-resident species, creating dysbiosis 
and developing multi-drug resistant bacteria and enteritis associated with microbial  replacement37,38. Keeping 
this in mind, the intestinal antimicrobial activity was tested against multi-drug resistant bacteria. Interestingly, 
indomethacin-treated mice receiving oral probiotic supplementation displayed an important reduction in the 
CFU/ml of Klebsiella pneumoniae and E. aerogenes multi-resistant (Fig. 5) compared to those animals on a con-
ventional diet receiving the indomethacin injection. These results clearly highlight probiotic consumption as an 
effective therapeutic alternative to many traditional antibiotics due to its lower possibility of generating resistance 
mechanisms compared to antibiotics, as well as for the safety of its use, as they are endogenous host peptides.
Figure 8.  Microbial population in the large intestine. Balb/c mice with an indomethacin-induced intestinal 
inflammatory process receiving a conventional diet (Indo) or oral probiotic supplementation (Lc 431 + Indo 
and Lp 1518 + Indo) for 7 and 5 days, respectively. At the end of this time, samples of the large intestine were 
collected and total anaerobic bacteria, lactobacilli, and enterobacterial population were analyzed by plate count 
agar. (A) Results were expressed as CFU/ml per gram of large intestine (mean ± S.E.M). Three independent 
experiments were performed. The line at the top of the bars indicates comparison between the two groups. 
*p < 0.05, **p < 0.01. (B) Mean scores of total bacterial population data in the experimental animals. Results are 
expressed as the ratio/relationship between each group and healthy controls.
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No less important is the fact that L. casei CRL 431 and L. paracasei CNCM I-1518 administered in our 
intestinal inflammatory model were also able to modulate the aberrant local and systemic immunity extensively 
reported in IBD by dampening proinflammatory pathways (Figs. 6 and 7). Furthermore, IL-10, the critical immu-
noregulatory cytokine in maintaining intestinal homeostasis and symbiosis with enteric microbiota, significantly 
increases upon probiotic lactobacilli interventions compared to animals with intestinal inflammation receiving 
a conventional diet (Fig. 6). These results became more relevant after Scheinin et al.’s finding that anti-TNF anti-
body therapy starting at 4 weeks markedly ameliorated the  disease39. Moreover, children affected by mutations in 
the IL-10 receptor are more likely to suffer from very early-onset of  IBD40. Recently, therapies based on restoring 
anti-inflammatory signals, by exploiting the tolerogenic potential of cytokines (interleukin-10, transforming 
growth factor-β, granulocyte macrophage colony-stimulating factor), immune cells (regulatory T cells, tolero-
genic dendritic cells), or mesenchymal stem cells, have emerge as effective alternatives with fewer side  effects41.
A more recent therapeutic strategy for IBD targets on oxidative  stress8. During mucosal inflammation, intes-
tinal epithelial cells (IECs) as well as neutrophils and macrophages produce superoxide and nitric oxide. These 
ROS damage cytoskeleton proteins and lead to alterations in tight junctions and epithelial permeability in IECs 
which in term result in barrier  disruption42. We postulate that the inflammation initiated by the high levels of 
ROS and NO production in our model of intestinal inflammation finally causes mucosal injuries accompanied 
by alterations in IECs, such as Goblet cell loss, crypt cell hyperplasia, and ulceration (Figs. 2, 3 and 4). Notably, 
the consumption of Lc 431 and Lp 1518 during an intestinal inflammatory process, through a reduction in local 
secretion of proinflammatory cytokines decreases ROS and NO production by peritoneal macrophages (Fig. 7) 
and preserves the integrity of the intestinal epithelial barrier.
A still unanswered question is whether the observed microbial dysbiosis is a cause or a consequence of 
intestinal inflammation. Unquestionably, while in a healthy intestine the Firmicutes and Bacteroidetes phyla 
predominate and contribute to the production of epithelial metabolic substrates, in IBD patients the micro-
biota is characterized by a relative lack of these filum, and an over-representation of Enterobacteriaceae and 
 Fusobacteria43,44. Moreover, a significantly reduced biodiversity in the fecal microbiome of IBD patients compared 
to that in healthy controls has also been  reported45,46. Interesting, the presence of a dysbiotic microbiota that 
appears after antibiotic treatment, imprints colonic invariant natural killer T (iNKT) and CD4 + T cells toward 
a pro-inflammatory phenotype that contributes to aggravate intestinal  inflammation38. Considering those facts, 
our results in which probiotic consumption modulates the intestinal microbiota in an intestinal inflammatory 
process by increasing the lactobacilli and anaerobes and reducing the enterobacteria become more relevant 
(Fig. 8). This beneficial microbiota would be involved in several protective, structural, and metabolic functions 
that prevent the initiation of an inflammatory process and plays a pivotal role in gut homeostasis.
These results together place L. casei CRL 431 and L. paracasei CNCM I-1518 at the cutting edge of the novel 
strategies that are able to reduce intestinal inflammation. Restoring impaired regulatory immune cell activity by 
correcting dysbiosis and defective antimicrobial activity is a safe and highly promising therapeutic approach to 
managing an intestinal inflammatory process in a more physiological, safer and sustained manner.
Probiotics emerge as a promising cost-effective therapeutic and preventive strategy to keep intestinal health 
in patients on non-steroidal anti-inflammatory drug treatment. Probiotics reinforce the intestinal epithelial bar-
rier and preserve intestinal homeostasis targeting several points, namely, Goblet and Paneth cells, antimicrobial 
activity of the intestinal fluids, balance between pro-inflammatory/regulatory cytokines, oxidative stress-related 
signaling pathways, and the intestinal microbiota.
Materials and methods
Bacteria. Lactobacillus casei CRL 431 from the CERELA culture collection and Lactobacillus paracasei 
CNCM I-1518 provided by DANONE Argentina were used as probiotic bacteria. These strains were activated by 
incubation for 16 h at 37 °C in sterile Man-Rogosa-Sharpe (MRS) broth (Britania, Argentina).
Salmonella enterica serovar Typhimurium was obtained from the Bacteriology Department, Hospital del 
Niño Jesús, Tucuman, Argentina. Staphylococcus aureus ATCC 25923, and two human isolated multi-drug 
resistant bacteria: Enterobacter aerogenes (6627734453176010, resistant to: ampicillin, ampicillin/sulbactam, 
piperacillin/tazobactam, cephalotin, cefotaxime, ceftazidime, cefepime, imipenem, meropenem, nalidixic acid, 
ciprofloxacin; susceptible to: amikacin, gentamicin, colistin and trimethoprim/sulfamethoxazole), and Klebsiella 
pneumoniae (resistant to: ampicillin ampicillin/sulbactam, piperacillin/tazobactam, cephalotin, cefotaxime, cef-
tazidime, cefepime, imipenem, meropenem, amikacin, gentamicin, nalidixic acid, ciprofloxacin, nitrofurantoin, 
trimethoprim/sulfamethoxazole; susceptible to: colistin, were kindly provided by Mariel Cáceres, Bacteriology 
Laboratory, Hospital Ángel C. Padilla, Tucumán. Aliquots of these bacteria from an overnight culture were 
placed in 5 ml of sterile Brain Heart Infusion (BHI) broth and incubated at 37 °C to reach exponential grown 
phase  (DO600 nm = 0.6).
Experimental animals and diet. Six to eight weeks old BALB/C mice provided by CERELA-CONICET 
(Tucumán, Argentina) were used. Animals were maintained in a room with a 12-h light/dark cycle at 22 ± 2 °C 
and fed with a balanced commercial diet ad libitum.
Lactobacillus bacteria overnight cultures were grown at 37° C in 5 ml sterile MRS broth. The cells were 
harvested by centrifugation at 5000 g for 10 min, washed three times with phosphate saline solution (PBS) and 
finally resuspended in 10% non-fat milk. The final concentration of probiotic bacteria was 1 × 108 CFU/ml, a 
concentration extensively used by our  group47,48. Bacterial suspensions were diluted 1:30 in water and adminis-
tered ad libitum to the mice. The suspension was renewed every day and administered for 7 days to groups fed 
with L. casei CRL 431 and for 5 days to mice fed with L. paracasei CNCM I-1518. These have been shown to be 
the periods required for an optimal activation of the intestinal immune system for each  strain49,50.
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BALB/C mice (6 per group) were supplemented with: Lactobacillus casei CRL 431 (Lc 431), Lactobacillus para-
casei CNCM I-1518 (Lp 1518), or water, for 7 and 5 days, respectively. In these animals an intestinal inflammation 
was induced by two subcutaneous injections of 7.5 mg/kg/day of  indomethacin51) on the last two days of the 
experiment protocol. Groups were as follows: Lc 431 + Indo; Lp1518 + Indo; and Indo (control of inflammation).
Additional controls, fed with Lc 431, Lp 1518 or water, respectively, received 2 injection of PBS (Lc 431; Lp 
1518 and healthy controls, respectively). The weight of the animals was recorded every two days. Fur appearance 
of each mouse was analyzed, according to Shrum  Bradly52. On day 8, mice were euthanized by cervical dislocation 
after been anesthetized with ketamine-xylazine (80 mg/kg and 10 mg/kg, respectively). Samples of blood, intesti-
nal fluids, large and small intestine, as well as liver and spleen were taken, and their weight and length registered.
A red blood cell test was performed in a Cell-Dyn Ruby analyzer (Abbott) on blood samples taken from 
experimental mice on the day of their sacrifice.
All animal protocols were preapproved by the Animal Protection Committee of CERELA (CRL-BIOT-LI-
2017/3B) and conducted in accordance with the guidelines established by the Consejo Nacional de Investiga-
ciones Científicas y Técnicas (CONICET) and the  NHI53,54.
Histological studies. Small intestine samples fixed in a 10% PBS-formaldehyde solution, pH = 7, for 24 h, 
were then dehydrated at increasing ethanol concentrations (30 to 100%), including in paraffin, sectioned in 4 
micron slices, colored with hematoxylin–eosin and examined by light microscopy. The severity of intestinal 
inflammation was graded from 0 to 4: 0, no leukocyte infiltration; 1, low level of leukocytic infiltration; 2, moder-
ate level of leukocytic infiltration; 3, high level of leukocytic infiltration, and 4, transmural  infiltration55. A blind 
histological test of the small intestine was performed, analyzing 100 intestinal crypts in 5 slices of each organ. 
H&E stain allows the identification of Paneth cells based on their distinctive granule staining pattern. Addition-
ally, villus length and number of Goblet cells in each tissue were analyzed.
Analyses of large intestine microbiota. Large intestines were removed in aseptic conditions, weighed 
and placed in tubes containing 5 ml of peptone water (0.1%). Then the samples were homogenized using a tissue 
microhomogenizer (MSE, England). Serial dilutions were performed and aliquots were spread on the surface of 
different agarized media: Reinforced Clostridial Agar (RCA) for total anaerobic bacteria, MRS for total Lactoba-
cilli and MacConkey for total enterobacteria. MRS y MacConkey were aerobically incubated at 37 °C for 48 and 
24 h respectively; RCA was anaerobically incubated at 37 °C for 120 h.
Analyses of bacterial translocation. Liver and spleen were removed, weighed and placed in tubes con-
taining 3 ml of peptone water (0.1%). Then the organs were homogenized and aliquots were spread on the sur-
face of MRS and MacConkey media, in pure state and half dilution. Both media were aerobically incubated at 
37 °C for 24 h for MacConkey and 48 h for MRS.
Ex vivo analyses of the antimicrobial activity. The antimicrobial activity from the intestinal fluids of 
mice were determined as described in  Cazorla23. Briefly, the small intestines were removed and their content was 
collected by the passage of 0.5 ml of 10 mM sodium phosphate buffer, pH = 7.4 along the intestine. Intestinal flu-
ids were centrifuged at 1300 xg/4 °C for 15 min and the supernatants incubated in the presence of the pathogenic 
bacteria. Exponential growth suspensions of S. Thyphimurium, S. aureus, E. aerogenes, K. pneumoniae were 
washed twice in 10 mM sodium phosphate buffer and 10 µl (5 × 106 UFC) of each strain was incubated at 37 °C 
for 2 h in the presence of 50 µl of intestinal fluids. Serial dilutions of these mixtures were spread in duplicate in 
BHI agar and incubated at 37 °C for 24 h for CFU count determination.
Cytokine determination. Intestines and intestinal fluids were collected from mice. Then, intestinal epi-
thelial cells (IECs) were isolated according to  Canali56 with some modifications. Briefly, small intestines were 
removed and washed twice in cold PBS. After discarding all Peyer Patches, the small intestines were opened lon-
gitudinally, washed with 100 µg/ml gentamicin in PBS, and then, incubated with 8% FBS, 100 µg/ml gentamicin, 
1 mM dithiothreitol, 30 mM EDTA in PBS for 15 min at room temperature. Segments were then incubated by 
shaking, with 100 µg/ml gentamicin, 10 mM EDTA in RPMI at 37 °C for 15 min. Supernatant was collected 
and centrifuged for 5 min at 300 × g. The pellet was washed twice with RPMI 100 µg/ml gentamicin and finally 
adjusted to 1 × 106 IEC/ml. Cells were transferred to six-well plates and incubated for 24 h at 37 °C 5%  CO2. 
Supernatants were recovered for cytokine determination.
TNF-α and IL-10 were determined by enzyme-linked immunosorbent assay according to the manufacturer’s 
instructions (BD OptEIA; BD Biosciences, USA).
Enzyme markers of inflammatory process and tissue damage. Levels of C-reactive protein (CRP) 
and lactate dehydrogenase (LDH) were analyzed in mice serum, following instructions from the commercial kits 
(GT Lab, Argentina).
Ex vivo determination of ROS and NO production. Cellular production of ROS was analyzed using 
H2DCFDA-related labelling. H2DCFDA (Sigma), an uncharged and non-fluorescent compound, freely diffuses 
across membranes in cells where it is hydrolyzed by esterase, and further oxidized by ROS into dichlorofluo-
rescein (DCF), a strong green fluorescent substance that cannot pass through the cell membrane. Cells (1 × 106) 
isolated from murine peritoneal cavity were washed with PBS, and incubated with 10 µmol/l H2DCFDA at 37 °C 
for 1 h in the dark, then washed and resuspended in PBS. Cellular H2DCFDA-related fluorescence that reflects 
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ROS formation was thereafter measured by flow cytometry using a BD FACSCalibur TM flow cytometer (BD 
Biosciences), and data were analyzed using Flow Jo software (Tree Star).
Additionally, 1 × 106 cells isolated from the murine peritoneal cavity were seeded in a 24-well plate and incu-
bated for 18 h at 37 °C 5%  CO2. Later, supernatants were removed and stored at -80 °C for cytokine and nitric 
oxide (NO) determination. Cytokines were determined using the corresponding enzyme-linked immunosorbent 
assay set according to the manufacturer’s instructions (BD OptEIA; BD Biosciences, USA).
The amount of NO released into the culture medium by macrophage cells was measured using Griess reagent. 
The reaction products were measured in a spectrophotometer at 550 nm, and their concentration was subse-
quently determined on a curve constructed with known concentrations of  NaNO2.
Statistical analyses. Results are presented as means ± SEM. GraphPad Prism 5.0 software (GraphPad 
Software Inc., San Diego, CA) was employed to carry out calculations. Results presented are representative of 
three independent experiments. The statistical significance was determined by one-way analysis of variance 
(ANOVA), using the Kruskal–Wallis  test57. P values of < 0.05 were considered to be statistically significant.
The radar chart tool in Microsoft Excel 2016 was used for a comparative study. Results were expressed as the 
relation of the experimental and healthy control animals.
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